Thirty two consecutive patients (age range 6 months-13*4 years) with severe reflux oesophagitis were randomised to a therapeutic trial for eight weeks during which they received either standard doses of omeprazole (40 mg/day/1*73 m2 surface area) or high doses of ranitidine (20 mg/kg/day). Twenty five patients completed the trial (12 on omeprazole, 13 on ranitidine). At entry and at the end of the trial patients underwent symptomatic score assessment, endoscopic and histological evaluation of the oesophagus, and simultaneous oesophageal and gastric pH measurement; results are given as median (range). Both therapeutic regimens were effective in decreasing clinical score (omeprazole before 24-0 (15-33), after 9-0
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Thirty two consecutive patients (age range 6 months-13*4 years) with severe reflux oesophagitis were randomised to a therapeutic trial for eight weeks during which they received either standard doses of omeprazole (40 mg/day/1*73 m2 surface area) or high doses of ranitidine (20 mg/kg/day). Twenty five patients completed the trial (12 on omeprazole, 13 on ranitidine). At entry and at the end of the trial patients underwent symptomatic score assessment, endoscopic and histological evaluation of the oesophagus, and simultaneous oesophageal and gastric pH measurement; results are given as median (range). Both therapeutic regimens were effective in decreasing clinical score (omeprazole before 24-0 (15-33), after 9-0 (0-18); ranitidine before 19 5 , after 9-0 (6-12)), in improving the histological degree of oesophagitis (omeprazole before 8-0 (6-10), after 2-0 (0-60); ranitidine before 8-0 (8-10), after 2-0 (2-6)), and in reducing oesophageal acid exposure, measured as minutes of reflux at 24 hour pH monitoring (omeprazole before 129*4 (84-217), after 44-6 (0. ; ranitidine before 207-3 (66-306), after 58-4 (32-128)) as well as intragastric acidity, measured as median intragastric pH (omeprazole before 2-1 (1.0-3.0), after 5S1 (2.2-7.4); ranitidine before 1*9 (1.6-4), after 3-4 (2-3-5.3)). Serum gastrin concentration was >150 ng/l in four patients on omeprazole and in three patients on ranitidine. It is concluded that in children with refractory reflux oesophagitis high doses of ranitidine are comparable with omeprazole for the healing ofoesophagitis and relief of symptoms; both drugs resulted in efficacious reduction of intragastric acidity and intraoesophageal acid exposure. ( It is generally agreed that GOR disease in childhood exhibits a more benign clinical course after medical treatment compared with adults.'0 Nevertheless, severe reflux disease is common in children and can be responsible for significant morbidity and life threatening events'l; furthermore, surgery is not uncommonly performed in children with persistent or intractable GOR disease. '2 In this study we have compared omeprazole with ranitidine given at high doses in children with GOR disease resistant to traditional antisecretory treatment associated with prokinetics. We wished to evaluate the clinical efficacy and the effect on oesophagitis and on both oesophageal and gastric acidity of the two therapeutic regimens.
Patients and methods Thirty two consecutive patients (age range 6 months-13 4 years; 16 boys and 16 girls) were enrolled in this study. These patients had previously received a diagnosis of GOR oesophagitis, based on 24 hour intraoesophageal pH monitoring and endoscopy with histology of the oesophageal mucosa. All had been unresponsive to an antireflux treatment including combined administration of ranitidine (8 mg/kg/day, given in two doses) and cisapride (0-8 mg/kg/day, given in three doses) for eight weeks. Unresponsiveness was defined as persistence of GOR symptoms and oesophagitis as detected by endoscopy and histology. None of the patients entering into the study had received combined treatment of cisapride and ranitidine for a period longer than eight weeks.
Before enrolment in the study, patients underwent symptomatic assessment, 24 hour intraoesophageal and intragastric pH measurement, and endoscopy of the oesophagus with biopsy. Patients were randomised to an eight week therapeutic trial of either omeprazole (40 mg/day/1 73 m2 surface area) given each morning or high doses of ranitidine (20 mg/kg/day) morning and evening. Oesophageal strictures, systemic extraintestinal Twenty four hour combined measurement of intraoesophageal and intragastric pH was performed with two flexible pH glass electrodes (Ingold M 1-5, Urdorf, Switzerland) passed through the naso-oesophageal route and positioned in the distal oesophagus and in the gastric corpus, respectively. The tip of the oesophageal electrode was located at the 87% of the distance between nares and lower oesophageal sphincter as determined according to Strobel's formula in patients under the age of 1 year.'3 In subjects older than 1 year or over 1 metre in height the tip of the electrode was positioned fluoroscopically so that it laid over the third vertebral body above the diaphragm throughout the respiratory cycle.'4 The tip of the intragastric electrode was located in the gastric corpus under fluoroscopy and was checked again the following day, at the end of the test. A silver/silver chloride reference electrode was applied to the chest skin. The measuring electrodes were carefully calibrated at the beginning and at the end of each study using commercially available standard buffer solutions (pH 4 0 and pH 7-0, Beckman); drift of the electrodes were accepted if less than 0-2 pH units. GOR was defined whenever the distal oesophageal pH dropped to less than 4-0 for at least 20 seconds. The electrodes were connected with a portable battery operated recorder (Proxima 'Light', Synectics, Milan); data recorded were transferred to an IBM personal computer and analysed by Esophogram software 5-4 (Synectics, Milan).
The following intraoesophageal and intragastric pH parameters were measured: the time the oesophageal pH was <4 0 (oesophageal exposure acid time); intragastric median pH; intragastric hydrogen activities (mMol/1) that were converted from the pH values using a standard table15; and the time the intragastric pH was less than 4 0 and 2-0. During the pH test patients were provided with standardised meals for their age. The meals were administered at a predetermined time for each patient. No beverages with pH below 4 0 were given and no food was allowed during the intervals between meals. All the pH studies were started at 8-00 am, after an overnight fast; all patients were requested to stop drugs affecting gastrointestinal motility and reducing gastric acid secretion for at least one week before the pH study. The oesophageal and gastric pH studies were performed at the beginning and at the end of the trial; the final pH study was done while patients were still receiving drugs.
Endoscopy of the oesophagus was performed with a paediatric fibreoptic endoscope (model GIFPQ20, Olympus, Torino) with a bioptic channel having 2-8 mm diameter. Two biopsy specimens were taken from the distal oesophageal mucosa, avoiding biopsies from the distal 20% of the oesophagus. Specimens were examined for the following features: basal cell zone hyperplasia, elongation of the papillae, ingrowth of vessels in the papillae, presence of intraepithelial eosinophils and/or neutrophils, and findings of mucosal erosions or ulcerations. pretrial values (omeprazole 2-0 (0-6), p<0 01; ranitidine 2-0 (2-6), p<001). Healing of oesophagitis (return to grade 0 or grade 2 of histological score) occurred in nine patients on omeprazole and in eight patients on high doses of ranitidine. Endoscopy after the trial revealed isolated small erosions affecting the distal oesophagus in three patients treated with omeprazole and in five patients on ranitidine; oerythema and oedema of distal oesophageal mucosa were observed in five patients on omeprazole and in six patients on ranitidine; oesophageal mucosa appeared normal in four patients treated with omeprazole and in two with ranitidine. Both therapeutic regimens decreased markedly oesophageal acid exposure time as well as intragastric acidity (table 3) . Table 4 reports the percentage improvement of intraoesophageal and intragastric pH variables in the two treatment groups.
Three patients on ranitidine and four on omeprazole had fasting serum gastrin values > 150 ng/l at the end of the study. The highest reported serum gastrin concentration was 346 ng/l for the omeprazole group and 482 ng/l for the ranitidine group. No serious adverse events to require discontinuing treatment and no abnormalities in the laboratory results were observed.
At the end of the trial drug treatment was stopped; however, if symptoms reappeared, patients were treated with courses of cisapride and ranitidine at conventional doses, as omeprazole or high dose ranitidine were not considered for long term treatment. At a six month follow up after the end of the trial, seven patients previously treated with omeprazole and five with high dose ranitidine were still symptomatic and showed both abnormal oesopl.ageal acid exposure at prolonged pH monitoring and oesophagitis at endoscopy (and histology); two of them underwent antireflux surgery.
Discussion
This study is the first controlled randomised trial comparing omeprazole with high doses of ranitidine in children with severe GOR disease, refractory to conventional treatment with H2 blockers and prokinetics. Omeprazole inhibits the final step in acid production, that is the enzyme H+/K+ATPase in the parietal cells. 16 In several comparative studies in adults a clear superiority of omeprazole over standard doses of H2 blockers in healing oesophagitis and improving symptoms has been reported. [17] [18] [19] [20] [21] [22] The efficacy of omeprazole in healing peptic oesophagitis is also evident when the drug is compared with high doses of H2 antagonists.8 9 23 24 This has been attributed to a more complete and long lasting suppression of gastric acid secretion induced by omeprazole as compared with the currently available H2 receptor blockers. '6 25 In our study the rate of oesophagitis healing and symptom relief induced by omeprazole was comparable with that observed with high dose ranitidine; furthermore, both therapeutic regimens produced similar rates of decrease in oesophageal acid exposure and intragastric acidity. However, omeprazole was more effective than high dose ranitidine in increasing intragastric median pH; this might be due to a less sustained acid suppression by high dose ranitidine as compared to omeprazole in individual cases, but a partial lack of efficacy of ranitidine cannot be excluded. 25 These results seem to confirm the common belief that refractoriness of GOR disease is mainly due to inadequate inhibition of gastric acid secretion with the currently recommended doses ofH2 receptor blockers. 26 Administration of omeprazole to humans results in increased plasma gastrin concentrations because of marked suppression of gastric acidity.34 However, this increase is significantly lower than that occurring after complete anacidity of the stomach, such as in pernicious anaemia or in the experimental condition of antrum exclusion. 35 36 Furthermore, plasma gastrin concentrations after administration of omeprazole are lower and less sustained than those detected in classical hypergastrinaemic conditions such as Zollinger-Ellison syndrome. 37 There is some concern about the hypergastrinaemia detected in patients treated chronically with omeprazole, was long term studies of toxicity in animals indicate that enterochromoaffin-like cell carcinoids can arise in rats exposed life long to omeprazole.38 Recent studies in man, however, indicate that omeprazole, given at the recommended doses, does not affect gastric oxyntic endocrine cells. 39 In conclusion, children with severe reflux oesophagitis resistant to previous treatment with conventional doses of ranitidine, constitute a group that can be successfully treated with high doses of ranitidine or with omeprazole. Our study indicates that short term administration of omeprazole and high dose ranitidine are safe and effective. On the other hand, as the relapse rate of the disease seems to be unaffected by the drugs given for short period, some patients would require long term treatment. Data on long term administration of these drugs in children are very limited. This paper has been presented in abstract form at the XXVI Annual Meeting of the European Society for Paediatric Gastroenterology and Nutrition, Gothenburg, Sweden, 27 June-I July 1993. This paper is dedicated to Professor Salvatore Auricchio on his sixtieth birthday.
